Shopping Cart
- Remove All
Your shopping cart is currently empty
Solifenacin succinate (YM905) is a quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 50 mg | $30 | In Stock | |
| 100 mg | $53 | In Stock | |
| 500 mg | $118 | In Stock | |
| 1 g | $173 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock |
| Description | Solifenacin succinate (YM905) is a quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE. |
| In vivo | Solifenacin succinate is a novel muscarinic antagonist indicated for the treatment of overactive bladder syndrome. When co-administered with oxybutynin, Solifenacin effectively inhibits the mobilization of intracellular calcium mediated by muscarinic M3 receptors in isolated bladder smooth muscle cells of guinea pigs and submandibular gland cells of mice. |
| Synonyms | YM905 |
| Molecular Weight | 480.56 |
| Formula | C23H26N2O2·C4H6O4 |
| Cas No. | 242478-38-2 |
| Smiles | O(C(=O)N1[C@H](c2c(CC1)cccc2)c1ccccc1)[C@@H]1C2CCN(C1)CC2.O=C(O)CCC(=O)O |
| Relative Density. | 1.24g/cm3 |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (52.02 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.16 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.